Company · Healthcare
Australian company that developed a treatment for bronchiectasis
Sydney, NSW
Every investor coverage indicates participated in a round Pharmaxis raised.
The transaction that ended Pharmaxis's run as a startup, per published coverage. It closes the funding history too, where it is the ladder's last rung.
| Bought by | Kind | Announced | Price | Sources |
|---|---|---|---|---|
| - | IPO | 23 Aug 2005 | - | GBS Ventures (2 Nov 2020), GBS Ventures (17 Oct 2011), GBS Ventures (23 Aug 2005) |
Companies Pharmaxis acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Pharmaxis. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
GBS Ventures marks its fourth FDA drug approval as Hatchtech's head lice treatment Xeglyze clears the regulator, recalling earlier wins behind Picato, Synribo and Aridol with Australian biotech firms.
GBS Ventures announces it has fully wound down its 1998 biotech fund with returns in the top quartile of US peers, recalling portfolio listings, Dynamic Hearing's sale to Wolfson, and its $122.5m fourth fund.
Pharmaxis announced its Aridol Phase III asthma diagnostic trial has enrolled first patients across 28 US sites, with FDA marketing authorisation planned for 2006.
Pharmaxis priced a two-tranche global capital raising: a US public offering plus an Australian institutional placement, with combined net proceeds around US$58.6 million (A$80 million) to fund drug development and manufacturing.
Australian drug developer Pharmaxis has won NASDAQ approval to trade its ADRs under ticker PXSLY, issuing no new shares; SEC registration is expected around 26 August 2005 before trading begins.
Also GBS Ventures·GBS Ventures